Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in desmoid tumors
NCT01876082Phase 2Completed
- Sponsor
- Institut Bergonié
- Start
- Sep 2012
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pazopanib in desmoid tumor (2 arms), sponsored by Institut Bergonié. Primary endpoint: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1. Started Sep 2012; status: completed.
02
Drugs
pazopanib
03
Conditions
desmoid tumor
Beyond the preview
Go deeper on NCT01876082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01876082.